The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S26-S36 , December 2006

Practical Applications of Intravenous Diuretic Therapy in Decompensated Heart Failure

  • John G.F. Cleland, MD

      Affiliations

    • Department of Cardiology, University of Hull, Kingston-upon-Hull, United Kingdom
    • Corresponding Author InformationRequests for reprints should be addressed to John G. F. Cleland, MD, Department of Cardiology, University of Hull, Kingston-upon-Hull HU16 5JQ, United Kingdom.
    • ,
  • Alison Coletta, BSc

      Affiliations

    • Department of Academic Cardiology, Castle Hill Hospital, Kingston-upon-Hull, United Kingdom
    • ,
  • Klaus Witte, MD

      Affiliations

    • Department of Academic Cardiology, Castle Hill Hospital, Kingston-upon-Hull, United Kingdom

References 

  1. Fonarow GC. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Failure Reviews. 2004;9:179–185
  2. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe (Part 1: patient characteristics and diagnosis). Eur Heart J. 2003;24:442–463
  3. Cleland JG, Lalukota K, Seymour A. Calcium sensitizers in acute heart failure. In:  O’Connor CM,  Gattis SW,  Gheorghiade M,  Adams KF editor. Management of Acute Decompensated Heart Failure. Boca Raton, FL: Taylor & Francis CRC Press; 2005;p. 479–496
  4. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committee for Practice Guidelines (CPG) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  5. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–660
  6. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J. 2005;26:644–649
  7. Sackner-Bernstein JD. Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure. Curr Cardiol Rep. 2005;7:204–210
  8. Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol. 1993;22(suppl A):165A–171A
  9. Hutton I, McGhie AI, Martin W, Tweddel AC. A comparison of intravenous elantan and frusemide in patients with chronic cardiac failure. Cardiology. 1987;74(suppl 1):65–68
  10. Verma SP, Silke B, Hussain M, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10:38–46
  11. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393
  12. Brater DC. Pharmacology of diuretics. Am J Med Sci. 2000;319:38–50
  13. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol. 1999;19:581–597
  14. Dickstein K. EuroHeart Survey: changes in the management of heart failure from 2000 to 2005. EuroHeart Survey on Heart Failure I vs EuroHeart Survey on Heart Failure II. Available at: http://www.escar-dio.org/NR/rdonlyres/AF261B82-E3D2-49AC-B6B7-BA82D26C9EDC/0/Dickstein_FP2546.pdf. Accessed December 20, 2005.
  15. Dixon DW, Barwolf-Gohlke C, Gunnar RM. Comparative efficacy and safety of bumetanide and furosemide in long-term treatment of edema due to congestive heart failure. J Clin Pharmacol. 1981;21:680–687
  16. Follath F. Do diuretics differ in terms of clinical outcome in congestive heart failure?. Eur Heart J. 1998;19(suppl P):P5–P8
  17. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–F21
  18. Stroobandt R, Dodion L, Kesteloot H. Clinical efficacy of torasemide, a new diuretic agent, in patients with acute heart failure: a double blind comparison with furosemide. Arch Int Pharmacodyn Ther. 1982;260:151–158
  19. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–609
  20. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–395
  21. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–143
  22. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  23. Krämer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90–96
  24. De Pasquale CG, Dunne JS, Minson RB, Arnolda LF. Hypotension is associated with diuretic resistance in severe chronic heart failure, independent of renal function. Eur J Heart Fail. 2005;7:888–891
  25. Lesch M, Caranasos GJ, Mulholland JH. Controlled study comparing ethacrynic acid to mercaptomerin in the treatment of acute pulmonary edema. N Engl J Med. 1968;279:115–122
  26. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187–193
  27. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450–458
  28. Hariman RJ, Bremner S, Louie EK, et al. Dose-response study of intravenous torsemide in congestive heart failure. Am Heart J. 1994;128:352–357
  29. Sagar S, Sharma BK, Sharma PL, Wahi PL. A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. Int J Clin Pharmacol Ther Toxicol. 1984;22:473–478
  30. Lahav M, Regev A, Ra’anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725–731
  31. Brater DC. Resistance to loop diuretics: why it happens and what to do about it. Drugs. 1985;30:427–443
  32. Marsh JD, Nesto R, Glynn MA, Smith TW. Comparison of intravenous piretanide and furosemide in patients with congestive heart failure. J Cardiovasc Pharmacol. 1982;4:949–954
  33. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–1315
  34. Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol. 2004;44:1308–1310
  35. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–338
  36. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  37. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  38. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med. 1997;25:1969–1975
  39. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191–199
  40. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22
  41. Costello-Boerrigter LC, Boerrigter G, Burnett JC. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am. 2003;87:475–491
  42. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59:443–449
  43. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–1328
  44. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6
  45. Cleland JG, Gillen G, Dargie HJ. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J. 1988;9:132–141
  46. Emerman CL, DeMarco T, Costanzo MR, Peacock WF. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry. J Card Fail. 2004;10(suppl 4):S116;Abstract 368
  47. Mehta RL, Pascual MT, Soroko S, Chertow GM PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–2553
  48. Neuberg GW, Miller AB, O’Connor CM, et al. PRAISE Investigators Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38
  49. de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27:569–581
  50. Philbin EF, Cotto M, Rocco TA, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997;80:519–522
  51. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  52. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  53. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435
  54. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–776
  55. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  56. de Silva R, Nikitin NP, Bhandari S, Nicholson A, Clark AL, Cleland JG. Atherosclerotic renovascular disease in chronic heart failure: should we intervene?. Eur Heart J. 2005;26:1596–1605
  57. MacDowall P, Kalra PA, O’Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet. 1998;352:13–16
  58. Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet. 1988;2:551–552
  59. Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 2002;7:275–279
  60. Kennedy DJ, Colyer WR, Brewster PS, et al. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. Am J Kidney Dis. 2003;42:926–935
  61. Wheatley K. ASTRAL—the story so far. Journal of Renovascular Disease. 2003;2:1–2
  62. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973;288:1087–1090
  63. Johnston GD, Hiatt WR, Nies AS, Payne NA, Murphy RC, Gerber JG. Factors modifying the early nondiuretic vascular effects of furosemide in man: the possible role of renal prostaglandins. Circ Res. 1983;53:630–635
  64. Jhund PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:1234–1238
  65. Pickkers P, Dormans TP, Russel FG, et al. Direct vascular effects of furosemide in humans. Circulation. 1997;96:1847–1852
  66. Juhlin T, Björkman S, Gunnarsson B, Fyge Å, Roth B, Höglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail. 2004;6:909–916
  67. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501–508
  68. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157–164
  69. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263
  70. Yelton SL, Gaylor MA, Murray KM. The role of continuous infusion loop diuretics. Ann Pharmacother. 1995;29:1010–1014
  71. Aaser E, Gullestad L, Tollofsrud S, et al. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest. 1997;57:361–367
  72. Mojtahedzadeh M, Salehifar E, Vazin A, et al. Comparison of hemodynamic and biochemical effects of furosemide by continuous infusion and intermittent bolus in critically ill patients. J Infus Nurs. 2004;27:255–261
  73. Kramer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 1996;36:265–270
  74. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy. 2003;23:997–1020
  75. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res. 1998;18:121–128
  76. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;1:CD003178
  77. van Meyel JJ, Smits P, Dormans T, Gerlag PG, Russel FG, Gribnau FW. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 1994;235:329–334
  78. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71:146–150
  79. Dormans TP, Gerlag PG, Russel FG, Smits P. Combination diuretic therapy in severe congestive heart failure. Drugs. 1998;55:165–172
  80. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet. 1990;335:29–31
  81. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229–249
  82. Sigurd B, Olesen KH, Wennevold A. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J. 1975;89:163–170
  83. Stewart JH, Edwards KD. Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid. BMJ. 1965;5473:1277–1281
  84. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A–28A
  85. Agostoni PG, Marenzi GC, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol. 1993;21:424–431
  86. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–968
  87. Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047–2051
  88. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) Trial. J Am Coll Cardiol. 2005;46:2043–2046
  89. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart. 1996;75:349–351

PII: S0002-9343(06)01144-2

doi: 10.1016/j.amjmed.2006.09.014

The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S26-S36 , December 2006

Article Tools

* Image Usage & Resolution